Indalo Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States2-10 Employees

Indalo Therapeutics is a biopharmaceutical company focused on discovering and developing integrin antagonists to address serious fibrotic diseases, including nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its lead candidate, IDL-2965, has demonstrated antifibrotic activity in preclinical models and entered human trials in early 2019, with studies evaluating its effects across organ systems such as liver, lung, and kidney. The company’s work aims to provide orally dosed therapies that can contribute to disease modification in fibrosis, targeting patients with conditions characterized by progressive organ scarring. Based in Cambridge, Massachusetts, Indalo Therapeutics operates in the biotechnology research sector, building on a history of integrin-focused science and development expertise. The firm’s leadership has prior experience in advancing therapies for IPF, and its organization reflects a specialized focus on translating integrin biology into potential clinical interventions. A notable leadership development in 2019 included the appointment of Robert Jacks as President & CEO, with subsequent governance updates in early 2020.

Get verified Indalo Therapeutics emails free

Company overview Employee directory